RhumbLine Advisers’s Nuvectis Pharma NVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCT
RhumbLine Advisers's NVCT Position: Q3 2026 in Review
RhumbLine Advisers increased its Nuvectis Pharma (NVCT) stake by 13% in Q3 2026, buying an estimated $47.7K and bringing the position to 19,532 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #2852.
RhumbLine Advisers first reported a position in NVCT in Q2 2023 and has held it in 11 quarters since. 95 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.
- RhumbLine Advisers held 19,532 shares of Nuvectis Pharma worth $413K as of Q3 2026.
- RhumbLine Advisers bought 2,261 Nuvectis Pharma shares in Q3 2026, an estimated $47.7K.
- Nuvectis Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2852 holding.
- RhumbLine Advisers first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 11 quarters since.
- 95 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.